Figure 2. Effects of vorinostat or VPA in combination with idarubicin on cell viability. Cell lines were treated with increasing doses of VPA (0.25-3 mM) or vorinostat (0.075-1 μM) concomitantly with idarubicin at 0.5 nM in MOLT4 or 1.5 nM in HL60 cells daily for 3 days. Numbers on the y-axis represent the percentage of viable cells. (A) MOLT4 cells. (B) HL60 cells. IDA indicates idarubicin; VPA, valproic acid; and Vor, vorinostat. Error bars indicate standard deviation.
Figure 2.

Effects of vorinostat or VPA in combination with idarubicin on cell viability. Cell lines were treated with increasing doses of VPA (0.25-3 mM) or vorinostat (0.075-1 μM) concomitantly with idarubicin at 0.5 nM in MOLT4 or 1.5 nM in HL60 cells daily for 3 days. Numbers on the y-axis represent the percentage of viable cells. (A) MOLT4 cells. (B) HL60 cells. IDA indicates idarubicin; VPA, valproic acid; and Vor, vorinostat. Error bars indicate standard deviation.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal